{"entity":{"id":"tubulysin-payloads","kind":"term","name":"Tubulysin payloads","aka":["tubulysin antibody conjugates","tubulysin analog payloads"],"tldr":"Tubulysins are another family of drugs that disrupt the cell's scaffolding. Antibody-linked versions are being studied to deliver their cell-killing action more selectively.","summary":"Tubulysin derivatives are tubulin-directed payloads distinct from auristatins and maytansinoids. A primary comparison of tubulysin antibody conjugates found that conjugation mode and site changed payload stability, pharmacokinetics and efficacy in a gastric cancer xenograft model. Results from a peptide or small-molecule tubulysin conjugate should not be described as antibody-conjugate evidence.","asOf":"2026-11-08","links":[{"label":"Tubulysin conjugation site, stability and efficacy study (2025)","url":"https://doi.org/10.1002/open.202400522"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload","tubulin-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/tubulysin-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/"}]}}